(Q33366562)

English

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

26 July 2017

Gemcitabine versus cisplatin, epirubicin, fluorouracil, and gemcitabine in advanced pancreatic cancer: a randomised controlled multicentre phase III trial (English)

1 reference

Europe PubMed Central

26 July 2017

phase III clinical trial

0 references

multicenter clinical trial

0 references

pancreatic cancer

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Alessandro Passardi

object named as

Alessandro Passardi

11

0 references

Luca Antonio Aldrighetti

14

object named as

Luca Aldrighetti

1 reference

Europe PubMed Central

26 July 2017

author name string

Michele Reni

1

1 reference

Europe PubMed Central

26 July 2017

Stefano Cordio

2

1 reference

Europe PubMed Central

26 July 2017

Carlo Milandri

3

1 reference

Europe PubMed Central

26 July 2017

Paolo Passoni

4

1 reference

Europe PubMed Central

26 July 2017

Elisa Bonetto

5

1 reference

Europe PubMed Central

26 July 2017

Cristina Oliani

6

1 reference

Europe PubMed Central

26 July 2017

Gabriele Luppi

7

1 reference

Europe PubMed Central

26 July 2017

Roberto Nicoletti

8

1 reference

Europe PubMed Central

26 July 2017

Laura Galli

9

1 reference

Europe PubMed Central

26 July 2017

Roberto Bordonaro

10

1 reference

Europe PubMed Central

26 July 2017

Alessandro Zerbi

12

1 reference

Europe PubMed Central

26 July 2017

Gianpaolo Balzano

13

1 reference

Europe PubMed Central

26 July 2017

Carlo Staudacher

15

1 reference

Europe PubMed Central

26 July 2017

Eugenio Villa

16

1 reference

Europe PubMed Central

26 July 2017

Valerio Di Carlo

17

1 reference

Europe PubMed Central

26 July 2017

publication date

1 June 2005

1 reference

Europe PubMed Central

26 July 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

26 July 2017

6

1 reference

Europe PubMed Central

26 July 2017

6

1 reference

Europe PubMed Central

26 July 2017

369-376

1 reference

Europe PubMed Central

26 July 2017

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Definitive results of a phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil, and gemcitabine in stage IV pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The Memorial Pain Assessment Card. A valid instrument for the evaluation of cancer pain

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Comprehensive criteria for assessing therapy-induced toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting results of cancer treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Development of a disease specific quality of life (QoL) questionnaire module to supplement the EORTC core cancer QoL questionnaire, the QLQ-C30 in patients with pancreatic cancer. EORTC Study Group on Quality of Life.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Interpreting the significance of changes in health-related quality-of-life scores.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of clinical benefit of chemotherapy in patients with upper gastrointestinal cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Final results of a prospective trial of a PEFG (Cisplatin, Epirubicin, 5-Fluorouracil, Gemcitabine) regimen followed by radiotherapy after curative surgery for pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

End points and United States Food and Drug Administration approval of oncology drugs

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2805%2970175-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(05)70175-3

1 reference

Europe PubMed Central

26 July 2017

1 reference

Europe PubMed Central

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33366562&oldid=1977846000"